Well Referenced

Category: Cancer & Oncology Support

Supportive and adjunctive therapies for cancer prevention and treatment.

Ursolic acid activates the apoptosis of prostate cancer via ROCK/PTEN mediated mitochondrial translocation of cofilin-1

This study investigated the pro-apoptotic effects of ursolic acid (UA) on human prostate cancer LNCaP cells. UA treatment resulted in significant inhibition of cell proliferation and induction of apoptosis, as evidenced by increased activities of caspase-3 and caspase-9. Mechanistically, UA activated the ROCK1/PTEN signaling pathway, leading to the dephosphorylation and

Read More »
June 26, 2025 No Comments

Vitamin D, sunlight, and the epidemiology of prostate cancer

This 2012 review examines the relationship between vitamin D, sunlight exposure, and prostate cancer risk. Ecological studies indicate an inverse correlation between ultraviolet (UV) radiation levels and prostate cancer mortality. Human prostate cells possess receptors for 1,25-dihydroxyvitamin D, which exhibits anticancer effects in vitro and in animal models. While some

Read More »
June 26, 2025 No Comments

Urinary cadmium concentration and risk of breast cancer: a systematic review and dose-response meta-analysis

This systematic review and meta-analysis evaluated the association between urinary cadmium levels and breast cancer risk. Analyzing data from 2 cohort studies, 5 case-control studies, and 1 cross-sectional study (totaling 1,416 cases and 5,083 controls), the study found that higher urinary cadmium concentrations were associated with increased breast cancer risk.

Read More »
June 26, 2025 No Comments

α-Lipoic acid prevents the ionizing radiation-induced epithelial-mesenchymal transition and enhances the radiosensitivity in breast cancer cells

This 2020 study investigated the effects of α-lipoic acid (ALA) on ionizing radiation (IR)-induced epithelial-mesenchymal transition (EMT) and radiosensitivity in breast cancer cells. The findings revealed that ALA treatment inhibited IR-induced EMT by downregulating mesenchymal markers (e.g., vimentin, N-cadherin) and upregulating epithelial markers (e.g., E-cadherin). Additionally, ALA enhanced the radiosensitivity

Read More »
June 26, 2025 No Comments

β-D-glucan inhibits endocrine-resistant breast cancer cell proliferation and alters gene expression

This 2014 study examined the anticancer effects of β-D-glucan on various breast cancer cell lines, particularly those resistant to endocrine therapy. The compound significantly inhibited cell proliferation in endocrine-resistant lines (LCC9 and LY2) at low micromolar concentrations, while having limited effects on normal breast epithelial cells and triple-negative breast cancer

Read More »
June 26, 2025 No Comments

Repurposing Itraconazole as a Treatment for Advanced Prostate Cancer: A Noncomparative Randomized Phase II Trial in Men With Metastatic Castration-Resistant Prostate Cancer

This 2013 phase II trial evaluated the antifungal drug itraconazole as a potential therapy for chemotherapy-naïve men with metastatic castration-resistant prostate cancer (mCRPC). Forty-six patients were randomized to receive either low-dose (200 mg/day) or high-dose (600 mg/day) oral itraconazole. The primary endpoint was the 24-week prostate-specific antigen (PSA) progression-free survival

Read More »
June 26, 2025 No Comments

Re-examining Current Breast Cancer Screening: An Analysis of the 2009 U.S. Preventive Services Task Force Guidelines for Breast Cancer Screening

This 2015 policy analysis critiques the 2009 USPSTF breast cancer screening recommendations, which shifted from annual to biennial screening for women aged 50–74 and advised against routine screening for women aged 40–49. The authors assess data from the five years following the guideline revision and raise concerns about potential increases

Read More »
June 26, 2025 No Comments